KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Clinical trials for KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.

Never miss a new study

Get alerted when new KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear

Sign up with your email to follow new studies for KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill targets tough cancers: first human trial begins

Disease control Recruiting now

This early-stage study tests a new oral drug, KST-6051, in adults with advanced lung, pancreatic, colorectal, or other solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 145 participants who have not responded to standard trea…

Matched conditions: KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Phase: PHASE1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control

Last updated May 04, 2026 16:22 UTC

KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Get alerted when new KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear

New pill targets tough cancers: first human trial begins